Author:
T.A. Voronina, E.A. Ivanova
FGBNU "Research Institute of Pharmacology named after V.V. Zakusova ”, Moscow, Russia
Author:
T.A. Voronina, E.A. Ivanova
FGBNU "Research Institute of Pharmacology named after V.V. Zakusova ”, Moscow, Russia
Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova Stroke No. 4/2019
Summary:
the review presents data on the combined use of Mexidol in combination with drugs of various pharmacotherapeutic groups. Possessing the multimodal action mechanism and a wide range of pharmacological effects, Mexoling enhances the main effect of drugs both in the experiment and in the clinic, increases the effectiveness of therapy prescribed by patients in accordance with current federal standards, and also helps to reduce the severity of complications of diseases. The data on the efficiency and pathogenetic validity of the course combination therapy with other preparations presented in the review indicate the advisability of this approach for the treatment of cerebrovascular and cardiovascular diseases, diseases of the nervous system, open-angle glaucoma, alcohol intoxication and a number of other diseases. Key words: Mexidol, combined therapy, free radicals, lipid oxidation, ischemic stroke, myocardial infarction, coronary heart disease, epilepsy, glaucoma, alcohol intoxication.
Information is intended for medical and pharmaceutical workers. This information cannot serve as a replacement for a doctor’s consultation.
Source of photos and images Shutterstock.com